Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2024; 12(11): 1967-1973
Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1967
Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report
Guang-Di Zhou, Qin Li
Guang-Di Zhou, Affiliated to Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai 200092, China
Qin Li, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, Shanghai 200433, China
Author contributions: Li Q designed and performed the research; Both of Li Q and Zhou GD analyzed the data and wrote the paper.
Supported by the “The Role and Molecular Mechanism of C20orf116 in Ovarian Cancer Cells”, Changhai Hospital Youth Start-up Fund.
Informed consent statement: The patient’s permission to publication is obtained.
Conflict-of-interest statement: All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript.
CARE Checklist (2016) statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qin Li, MD, Lecturer, Surgeon, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai 200433, Shanghai, China. pekingli@163.com
Received: January 12, 2024
Peer-review started: January 12, 2024
First decision: January 31, 2024
Revised: February 8, 2024
Accepted: March 19, 2024
Article in press: March 19, 2024
Published online: April 16, 2024
Core Tip

Core Tip: When chemotherapy, poly adenosine diphosphate ribose polymerase inhibitors, and other treatments are ineffective for relapsed refractory ovarian cancer, anti-programmed death 1 immunotherapy may be the last resort.